Apogee Therapeutics shares are trading higher after Jefferies maintained a Buy rating on the stock and raised its price target from $37 to $75.
Portfolio Pulse from Benzinga Newsdesk
Apogee Therapeutics' stock price is on the rise following an upgrade from Jefferies, which maintained a Buy rating and increased the price target from $37 to $75.
March 06, 2024 | 7:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apogee Therapeutics' stock is expected to experience a positive short-term impact due to Jefferies' upgraded price target and maintained Buy rating.
The upgrade by Jefferies, a reputable financial services company, directly impacts investor sentiment towards Apogee Therapeutics. The significant increase in the price target reflects a strong vote of confidence in the company's future performance, likely leading to increased investor interest and potentially higher stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100